Korean J Ophthalmol.  2005 Mar;19(1):73-76. 10.3341/kjo.2005.19.1.73.

Treatment of Candida Chorioretinitis with Voriconazole

• Jang GJ
• Kim KS
• Shin WS
• Lee WK

• KMID: 1099089
• DOI: http://doi.org/10.3341/kjo.2005.19.1.73

Abstract

A 63-year-old female with candidemia following necrotizing pancreatitis developed clinical signs of chorioretinitis and underwent the systemic administration of voriconazole, after which anterior chamber inflammation and multiple, white, fluffy, chorioretinal lesions, under 1mm in diameter, were gradually resolved and visual acuity improved. We report the first Korean case of candida chorioretinitis successfully treated with the systemic administration of voriconazole.

Keyword

Candidemia; Candida chorioretinitis; Voriconazole

MeSH Terms

Antifungal Agents/*therapeutic use
Candidiasis/*drug therapy/microbiology
Chorioretinitis/*drug therapy/microbiology
Eye Infections, Fungal/*drug therapy/microbiology
Female
Fungemia/drug therapy
Humans
Middle Aged
Pyrimidines/*therapeutic use
Triazoles/*therapeutic use

Figure

• 

  Fig. 1 Fundus photograph showing (A) multiple, yellow-white lesions, less than 1mm in diameter, at the posterior pole, and (B) resolution 16 days after the systemic administration of voriconazole.

Reference

1. Brod RD, Flynn HW Jr, Clarkson JG, et al. Endogenous Candida endophthalmitis. Ophthalmology. 1990. 97:666–674.

2. Dellon AL, Stark WJ, Chetien PB. Spontaneous resolution of endogenous Candida endophthalmitis complicating intravenous hyperalimentation. Am J Ophthalmol. 1975. 79:648–654.

3. Stern GA, Fetkenhour CL, O'Grady RB. Intravitreal amphotericin B treatment of Candida endophthalmitis. Arch Ophthalmol. 1977. 95:89–93.

4. Robertson DM, Riley FC, Hermans PE. Endogenous Candida oculomycosis: report of two patients treated with flucytosine. Arch Ophthalmol. 1974. 91:33–38.

5. Edwards JE Jr, Lehrer RI, Stiehm ER, et al. Severe candidal infections: clinical perspective, immune defense mechanisms, and current concepts of therapy. Ann Intern Med. 1978. 89:91–106.

6. Sande MA, Mandell GL. Gilman AG, Goodman LS, Rall TW, Murad F, editors. Antimicrobial agents: antifungal and antiviral agents. The pharmacological basis of therapeutics. 1985. 7th ed. New York: Macmillan;chap. 54.

7. Marco F, Danes C, Almela M, et al. Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida blood stream isolates. Results from a six-year study (1996-2001). Diagn Microbiol Infect Dis. 2003. 46:259–264.

8. Johnson LB, Kauffman CA. Voriconazole: A New Triazole Antifungal Agent. Clin Infect Dis. 2003. 36:630–637.

9. Shah KB, Wu TG, Wilhelmus KR, Jones DB. Activity of Voriconazole against Corneal Isolates of Scedosporium Apiospermum. Cornea. 2003. 22:33–36.

10. Kim SW, Lee EK. A prospective study of intraocular Candidiasis. J Korean Ophthalmol Soc. 1997. 38:368–373.

11. Choi KS, Kim JS, Nam KR. Intraocular Candidiasis in babies with Candida sepsis. J Korean Ophthalmol Soc. 2000. 41:1563–1568.

12. Johnson EM, Szekely A, Warnock DW. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother. 1998. 42:741–745.

13. Cuenca-Estrella M, Ruiz-Diez B, Martinez-Suarez JV, et al. Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother. 1999. 43:149–151.

14. Carrillo AJ, Guarro J. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother. 2001. 45:2151–2153.

15. Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol. 2001. 39:954–958.

16. Meletiadis J, Meis F, Mouton JW. EUROFUNG Network. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother. 2002. 46:62–68.